Compare CDLX & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDLX | BWAY |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | Israel |
| Employees | N/A | 129 |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.5M | 674.2M |
| IPO Year | 2018 | N/A |
| Metric | CDLX | BWAY |
|---|---|---|
| Price | $0.62 | $14.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $2.25 | ★ $13.25 |
| AVG Volume (30 Days) | ★ 868.7K | 133.6K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $233,273,000.00 | N/A |
| Revenue This Year | N/A | $309.69 |
| Revenue Next Year | $8.82 | $26.21 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.57 | $10.01 |
| 52 Week High | $3.28 | $26.63 |
| Indicator | CDLX | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 27.89 | 40.25 |
| Support Level | $0.57 | $14.56 |
| Resistance Level | $1.23 | $16.63 |
| Average True Range (ATR) | 0.07 | 0.64 |
| MACD | -0.02 | -0.19 |
| Stochastic Oscillator | 13.69 | 2.61 |
Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone. At the core of its commerce media platform is the financial media network that it runs within its partners' digital channels, which includes online and mobile applications (the Cardlytics platform). Additionally, it operates an identity resolution platform that utilizes point-of-sale (POS) data, including product-level purchase data, to enable marketers to perform analytics and targeted loyalty marketing and also measure the impact of their marketing (the Bridg platform). It operates in three segments: the Cardlytics platform in the U.S.; the Cardlytics platform in the U.K.; and the Bridg platform. The majority of the revenue is derived from the Cardlytics platform.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.